PerkinElmer expands Chinese Dx offering further with $38m Shanghai Haoyuan buy
This article was originally published in Clinica
Executive Summary
PerkinElmer has boosted its presence in the Chinese molecular clinical diagnostics segment by purchasing Shanghai Haoyuan Biotech, a local infectious disease testing player. The deal, worth $38 million in cash, as well as additional revenue-based milestone payments, adds to the firm's existing footprint in the country gained partly through its 2009 acquisition of SYM-BIO Lifescience (www.clinica.co.uk, 9 September 2009).